Startseite Kongressberichte & Archiv ASCO20 Virtual Scientific Meeting Oral Sessions Hematologic Malignancies III

Hematologic Malignancies—Plasma Cell Dyscrasia

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)
Click also The Video Journal of Hematological Oncology (VJHemOnc) Link at the bottom of the page to watch a summary of the most important studies presented at ASCO 2020 in multiple myeloma
 
8500 First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
 
Paul G. Richardson, Annette J. Vangsted, Karthik Ramasamy, et al.
 
The abstract concludes: 
TEAEs of CC-92480 were mainly related to myelosuppression in heavily pretreated, including triple-class-refractory, RRMM pts. Promising activity with 48% ORR at therapeutic doses was observed. The study is ongoing to further optimize dose and schedule, with combination studies underway and dose expansion cohorts planned. Clinical trial information: NCT03374085.
————————————————————————————————————————————————————————————————————————————
 
8501 Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.
 
Meletios A. Dimopoulos, Sosana Delimpasi, Maryana Simonova, et al. 
 
The abstract concludes: 
BOSTON is the first phase 3 study to evaluate the clinical benefit of SVd for relapsed/refractory MM. The study met the primary endpoint: once weekly SVd significantly improved PFS and ORR compared to twice weekly Vd. Rates of PN were significantly reduced with numerically fewer deaths on SVd vs Vd. Full dataset will be presented at the meeting. Clinical trial information: NCT03110562.
 
 
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
————————————————————————————————————————————————————————————————————————————
 
8502 DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).
 
Ajay K. Nooka, Keith Stockerl-Goldstein, Hang Quach, et al.
 
The abstract concludes: 
In DREAMM-6, preliminary data demonstrate that the combination of belantamab mafodotin and BorDex has an acceptable safety profile, with no new safety signals identified. Funding: GlaxoSmithKline (207497). Drug linker technology licensed from Seattle Genetics; monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa. Clinical trial information: NCT03544281.
 
————————————————————————————————————————————————————————————————————————————
 
8503 Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.
 
Nikhil C. Munshi, Larry D. Anderson, Jr, Nina Shah, et al.
 
The abstract concludes: 
Ide-cel demonstrated deep, durable responses in heavily pretreated RRMM pts. Efficacy and safety reflected prior reports and support a favorable ide-cel clinical benefit-risk profile across the target dose range. Clinical trial information: NCT03361748.
————————————————————————————————————————————————————————————————————————————
 
8504 Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).
 
Sham Mailankody, Andrzej J. Jakubowiak, Myo Htut, et al.
 
The abstract concludes: 
Orva-cel at 300, 450, and 600 × 106 CAR+ T cells demonstrated manageable safety (CRS grade ≥3: 2%; NE grade ≥3: 4%) and compelling efficacy in heavily pretreated pts with RRMM, with a 91% objective response rate (ORR) and 39% complete response (CR)/stringent CR (sCR) rate. Updated results will be presented, including minimal residual disease, durability of response, and recommended phase 2 dose. Clinical trial information: NCT03430011.
 
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
————————————————————————————————————————————————————————————————————————————
 
8505 Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
 
Jesus G. Berdeja, Deepu Madduri, Saad Zafar Usmani, et al.
 
The abstract concludes: 
JNJ-4528 treatment led to responses in all pts. These responses were early, deep, and durable at a low dose of CAR-T cells with 26/29 (90%) pts progression free at median 9-mo follow-up. CRS was manageable in most pts, supporting outpatient dosing. Clinical trial information: NCT03548207.
————————————————————————————————————————————————————————————————————————————
 
8606 Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).
 
Parameswaran Hari, Marcelo C. Pasquini, Edward Allen Stadtmauer, et al.
 
The abstract concludes: 
Long term outcomes are similar using ITT, but as treated analysis suggested a PFS benefit for tandem autoHCT, driven mainly by pts with high risk MM. Len discontinuation even at 38 mo was associated with inferior PFS. Clinical trial information: NCT02322320.
————————————————————————————————————————————————————————————————————————————
 
8507 Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211).
 
Saad Zafar Usmani, Sikander Ailawadhi, Rachael Sexton, et al.
 
The abstract concludes: 
In the first randomized HRMM study reported to date, the addition of elotuzumab to RVd induction and maintenance did not improve patient outcomes. However, the PFS and OS seen in both arms of the study exceeded the original statistical assumptions and support the role for PI/IMiD combination maintenance therapy for this patient population. The S1211 data will serve as an important benchmark for future HRMM clinical trials. Clinical trial information: NCT01668719.
 
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
————————————————————————————————————————————————————————————————————————————
 
The Video Journal of Hematological Oncology (VJHemOnc): Suzanne Lentzsch, MD, PhD, Columbia University, New York, NY, USA, takes you through a selection of the most important studies presented at ASCO 2020 in multiple myeloma:

ASCO 2020 | Highlights in multiple myeloma at ASCO 2020

————————————————————————————————————————————————————————————————————————————
 
MORE ABSTRACTS:
 
Poster Discussion Session
Hematologic Malignancies—Plasma Cell Dyscrasia
 
Poster Session
Hematologic Malignancies—Plasma Cell Dyscrasia
 
ASCO Direct™ Focus – ASCO®20 Virtual Program  
Top presentations and expert interviews now available on demand!
Visit ascodirect2020.com and enter the following username „asco“ and password: „oncology"  
ASCO Direct Focus is an officially licensed online program for oncology professionals worldwide, providing complimentary access to an ASCO-curated selection of top presentations from the ASCO20 Virtual Scientific Program, plus expert commentaries.
Hematologic Malignancies (Abstracts #LBA3, 8500, 8502)
Access Content Now